Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study.

Berger GE, Wood SJ, Wellard RM, Proffitt TM, McConchie M, Amminger GP, Jackson GD, Velakoulis D, Pantelis C, McGorry PD.

Neuropsychopharmacology. 2008 Sep;33(10):2467-73. doi: 10.1038/sj.npp.1301628. Erratum in: Neuropsychopharmacology. 2009 Jan;34(2):535.

2.

Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial.

Berger GE, Proffitt TM, McConchie M, Yuen H, Wood SJ, Amminger GP, Brewer W, McGorry PD.

J Clin Psychiatry. 2007 Dec;68(12):1867-75.

PMID:
18162017
3.

Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: a longitudinal T2 relaxometry pilot study.

Wood SJ, Cocchi L, Proffitt TM, McConchie M, Jackson GD, Takahashi T, Pantelis C, McGorry PD, Berger GE.

Psychiatry Res. 2010 May 30;182(2):180-2. doi: 10.1016/j.pscychresns.2009.12.003.

PMID:
20413278
4.
5.
6.

Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation.

Wood SJ, Berger GE, Wellard RM, Proffitt TM, McConchie M, Berk M, McGorry PD, Pantelis C.

Neurobiol Dis. 2009 Mar;33(3):354-7. doi: 10.1016/j.nbd.2008.11.018.

PMID:
19118629
7.

Impaired glutamine metabolism in NMDA receptor hypofunction induced by MK801.

Brenner E, Kondziella D, Håberg A, Sonnewald U.

J Neurochem. 2005 Sep;94(6):1594-603.

8.

Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial.

Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, Hersch S, Vaddadi KS, Sword A, Horrobin DF, Manku M, Murck H.

Neurology. 2005 Jul 26;65(2):286-92.

PMID:
16043801
9.
10.

Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study.

Yoon SJ, Lyoo IK, Haws C, Kim TS, Cohen BM, Renshaw PF.

Neuropsychopharmacology. 2009 Jun;34(7):1810-8. doi: 10.1038/npp.2009.2.

11.

Amino acid metabolic processes in the temporal lobes assessed by proton magnetic resonance spectroscopy (1H MRS) in children with Down syndrome.

Śmigielska-Kuzia J, Boćkowski L, Sobaniec W, Kułak W, Sendrowski K.

Pharmacol Rep. 2010 Nov-Dec;62(6):1070-7.

12.

Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers.

Rhodes LE, Shahbakhti H, Azurdia RM, Moison RM, Steenwinkel MJ, Homburg MI, Dean MP, McArdle F, Beijersbergen van Henegouwen GM, Epe B, Vink AA.

Carcinogenesis. 2003 May;24(5):919-25.

PMID:
12771037
13.

Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies.

Fusar-Poli P, Berger G.

J Clin Psychopharmacol. 2012 Apr;32(2):179-85. doi: 10.1097/JCP.0b013e318248b7bb. Review.

PMID:
22367656
14.

Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial.

Emsley R, Niehaus DJ, Oosthuizen PP, Koen L, Ascott-Evans B, Chiliza B, van Rensburg SJ, Smit RM.

Psychiatry Res. 2008 Dec 15;161(3):284-91. doi: 10.1016/j.psychres.2007.06.029.

PMID:
18962989
15.
16.

Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.

Bustillo JR, Chen H, Jones T, Lemke N, Abbott C, Qualls C, Canive J, Gasparovic C.

JAMA Psychiatry. 2014 Mar;71(3):265-72. doi: 10.1001/jamapsychiatry.2013.3939.

PMID:
24402128
17.

Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals.

Wood SJ, Berger G, Velakoulis D, Phillips LJ, McGorry PD, Yung AR, Desmond P, Pantelis C.

Schizophr Bull. 2003;29(4):831-43.

PMID:
14989417
18.

Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.

Szulc A, Galinska B, Tarasow E, Waszkiewicz N, Konarzewska B, Poplawska R, Bibulowicz D, Simonienko K, Walecki J.

Pharmacopsychiatry. 2011 Jun;44(4):148-57. doi: 10.1055/s-0031-1279739.

PMID:
21710405
19.

Vigorous exercise increases brain lactate and Glx (glutamate+glutamine): a dynamic 1H-MRS study.

Maddock RJ, Casazza GA, Buonocore MH, Tanase C.

Neuroimage. 2011 Aug 15;57(4):1324-30. doi: 10.1016/j.neuroimage.2011.05.048.

PMID:
21640838
20.

Whole-brain glutamate metabolism evaluated by steady-state kinetics using a double-isotope procedure: effects of gabapentin.

Xu Y, Oz G, LaNoue KF, Keiger CJ, Berkich DA, Gruetter R, Hutson SH.

J Neurochem. 2004 Sep;90(5):1104-16.

Supplemental Content

Support Center